Myriad Genetics, Inc. (MYGN) EPS Estimated At $0.21; Huber Capital Management Has Cut Its Pfizer (PFE) Holding

October 13, 2017 - By Vivian Currie

Huber Capital Management Llc decreased Pfizer Inc (PFE) stake by 1.5% reported in 2017Q2 SEC filing. Huber Capital Management Llc sold 18,700 shares as Pfizer Inc (PFE)’s stock declined 3.45%. The Huber Capital Management Llc holds 1.23M shares with $41.27M value, down from 1.25 million last quarter. Pfizer Inc now has $216.41 billion valuation. The stock declined 0.08% or $0.03 reaching $36.31 per share. About 12.76 million shares traded. Pfizer Inc. (NYSE:PFE) has declined 2.76% since October 13, 2016 and is downtrending. It has underperformed by 19.46% the S&P500.

Analysts expect Myriad Genetics, Inc. (NASDAQ:MYGN) to report $0.21 EPS on November, 7.They anticipate $0.02 EPS change or 8.70% from last quarter’s $0.23 EPS. MYGN’s profit would be $14.35M giving it 43.38 P/E if the $0.21 EPS is correct. After having $0.30 EPS previously, Myriad Genetics, Inc.’s analysts see -30.00% EPS growth. The stock decreased 0.30% or $0.11 during the last trading session, reaching $36.44. About 492,392 shares traded. Myriad Genetics, Inc. (NASDAQ:MYGN) has declined 37.47% since October 13, 2016 and is downtrending. It has underperformed by 54.17% the S&P500.

Analysts await Pfizer Inc. (NYSE:PFE) to report earnings on November, 7. They expect $0.64 EPS, up 4.92% or $0.03 from last year’s $0.61 per share. PFE’s profit will be $3.81 billion for 14.18 P/E if the $0.64 EPS becomes a reality. After $0.67 actual EPS reported by Pfizer Inc. for the previous quarter, Wall Street now forecasts -4.48% negative EPS growth.

Investors sentiment decreased to 0.94 in 2017 Q2. Its down 0.01, from 0.95 in 2017Q1. It turned negative, as 58 investors sold PFE shares while 716 reduced holdings. 112 funds opened positions while 612 raised stakes. 4.02 billion shares or 1.07% less from 4.06 billion shares in 2017Q1 were reported. Thompson Rubinstein Mgmt Inc Or reported 1.2% of its portfolio in Pfizer Inc. (NYSE:PFE). Rothschild Asset Mngmt invested 0.9% in Pfizer Inc. (NYSE:PFE). 6.99M were accumulated by London Company Of Virginia. Berson And Corrado Inv Advsr reported 38,442 shares or 0.71% of all its holdings. Creative Planning holds 0.13% of its portfolio in Pfizer Inc. (NYSE:PFE) for 739,760 shares. Jupiter Asset Mngmt Ltd, a United Kingdom-based fund reported 741,108 shares. Folger Nolan Fleming Douglas Cap Mngmt reported 0.19% stake. Palouse Mgmt holds 2.95% or 241,779 shares in its portfolio. Pennsylvania Tru invested in 1.06% or 638,149 shares. Grandfield Dodd holds 82,899 shares. Cap Incorporated Ca owns 24,500 shares or 0.12% of their US portfolio. The California-based Regents Of The University Of California has invested 4.08% in Pfizer Inc. (NYSE:PFE). Diamond Hill Capital Mngmt holds 11.33 million shares or 2.05% of its portfolio. Allstate Corporation accumulated 163,992 shares or 0.29% of the stock. Oarsman Capital owns 40,898 shares for 0.63% of their portfolio.

Huber Capital Management Llc increased Golar Lng Partners Lp (NASDAQ:GMLP) stake by 219,511 shares to 1.76M valued at $35.42M in 2017Q2. It also upped Arconic Inc stake by 479,100 shares and now owns 1.18M shares. Bank Amer Corp (NYSE:BAC) was raised too.

Among 20 analysts covering Pfizer (NYSE:PFE), 8 have Buy rating, 1 Sell and 11 Hold. Therefore 40% are positive. Pfizer had 59 analyst reports since July 29, 2015 according to SRatingsIntel. The firm earned “Buy” rating on Wednesday, July 29 by Argus Research. The stock has “Outperform” rating by Credit Suisse on Monday, May 9. BMO Capital Markets maintained Pfizer Inc. (NYSE:PFE) on Tuesday, August 1 with “Hold” rating. On Monday, August 14 the stock rating was maintained by Cowen & Co with “Buy”. Goldman Sachs maintained the stock with “Neutral” rating in Monday, April 18 report. Jefferies maintained Pfizer Inc. (NYSE:PFE) on Tuesday, June 14 with “Buy” rating. The firm earned “Overweight” rating on Thursday, April 7 by JP Morgan. The firm has “Equal-Weight” rating by Barclays Capital given on Tuesday, December 1. The rating was maintained by Jefferies on Thursday, April 7 with “Buy”. The firm has “Neutral” rating by SunTrust given on Wednesday, November 25.

Investors sentiment decreased to 1.02 in Q2 2017. Its down 0.71, from 1.73 in 2017Q1. It worsened, as 28 investors sold Myriad Genetics, Inc. shares while 74 reduced holdings. 45 funds opened positions while 59 raised stakes. 78.85 million shares or 1.67% less from 80.18 million shares in 2017Q1 were reported. The Massachusetts-based Geode Ltd has invested 0.01% in Myriad Genetics, Inc. (NASDAQ:MYGN). Archford Strategies Ltd Liability holds 0.37% or 13,087 shares. 200,103 were reported by Bb&T Secs. First Republic Inv Mgmt reported 9,597 shares. Swiss State Bank owns 114,600 shares. Guggenheim Capital Ltd Liability accumulated 199,553 shares. Piedmont Invest Advsrs Ltd Limited Liability Company has 0.07% invested in Myriad Genetics, Inc. (NASDAQ:MYGN). Baillie Gifford & Company reported 9.67M shares. Cibc Asset Mgmt Inc holds 0% or 8,451 shares. Hartford Invest Mgmt holds 9,990 shares or 0% of its portfolio. Mackenzie owns 210,697 shares for 0.03% of their portfolio. Manufacturers Life Insur The has invested 0% in Myriad Genetics, Inc. (NASDAQ:MYGN). Bank Of New York Mellon accumulated 0.01% or 935,217 shares. Morgan Stanley holds 195,780 shares. Hall Laurie J Trustee accumulated 300 shares.

Myriad Genetics, Inc. is a molecular diagnostic company. The company has market cap of $2.49 billion. The Firm is engaged in the discovery, development and marketing of transformative molecular diagnostic tests. It has a 116.03 P/E ratio. The Firm operates through two divisions: diagnostics and other.

Among 19 analysts covering Myriad Genetics (NASDAQ:MYGN), 2 have Buy rating, 4 Sell and 13 Hold. Therefore 11% are positive. Myriad Genetics had 44 analyst reports since July 21, 2015 according to SRatingsIntel. Leerink Swann maintained Myriad Genetics, Inc. (NASDAQ:MYGN) on Wednesday, May 4 with “Market Perform” rating. Gabelli initiated the shares of MYGN in report on Tuesday, July 21 with “Buy” rating. Mizuho maintained the shares of MYGN in report on Tuesday, September 15 with “Neutral” rating. The stock of Myriad Genetics, Inc. (NASDAQ:MYGN) has “Equal-Weight” rating given on Wednesday, August 10 by Barclays Capital. The stock of Myriad Genetics, Inc. (NASDAQ:MYGN) earned “Hold” rating by Gabelli on Wednesday, August 10. The firm earned “Market Outperform” rating on Wednesday, May 4 by Avondale. Morgan Stanley maintained it with “Underweight” rating and $21 target in Wednesday, August 10 report. On Friday, September 15 the stock rating was maintained by Cowen & Co with “Hold”. The firm earned “Hold” rating on Monday, August 14 by Cowen & Co. Piper Jaffray maintained the stock with “Overweight” rating in Tuesday, September 15 report.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


Twitter Auto Publish Powered By : XYZScripts.com